1921
Volume 77, Issue 4
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Azithromycin was compared with meglumine antimoniate for treatment of patients with cutaneous leishmaniasis. Patients were randomized to receive oral azithromycin, 500 mg/day (22 patients) or intramuscular meglumine antimoniate, 10 mg Sb/kg/day (23 patients), both for 28 days, with a second cycle of 15 days if necessary, and followed-up for one year after completion of treatment. Efficacy, defined as complete re-epithelization without relapse for 12 months after completing therapy, was 82.6% (95% confidence interval [CI] = 67–98%) for meglumine antimoniate and 45.5% (95% CI = 25–66%) for azithromycin. All patients who failed treatment with azithromycin were treated with meglumine antimoniate and clinically cured. Azithromycin was well tolerated; meglumine antimoniate caused arthralgias and local symptoms in 78% of the patients. In 17 cases, species identification was obtained; () was identified in all of them. For the treatment of American cutaneous leishmaniasis caused by () , meglumine antimoniate is significatively more efficacious than azithromycin, which was clinically curative in almost half of the patients and well-tolerated.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.2007.77.640
2007-10-01
2017-09-22
Loading full text...

Full text loading...

/deliver/fulltext/14761645/77/4/0770640.html?itemId=/content/journals/10.4269/ajtmh.2007.77.640&mimeType=html&fmt=ahah

References

  1. Desjeux P, 1996. Leishmaniasis. Public health aspects and control. Clin Dermatol 14 : 417–423.
  2. Murray HW, Berman JD, Davies CR, Saravia NG, 2005. Advances in leishmaniasis. Lancet 366 : 1561–1577.
  3. Marsden PD, 1986. Mucosal leishmaniasis (“espundia” Escomel, 1911). Trans R Soc Trop Med Hyg 80 : 859–876.
  4. Osorio LE, Castillo CM, Ochoa MT, 1998. Mucosal leishmaniasis due to Leishmania (Viannia) panamensis in Colombia: clinical characteristics. Am J Trop Med Hyg 59 : 49–52.
  5. Croft SL, Coombs GH, 2003. Leishmaniasis–current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol 19 : 502–508.
  6. Frank FM, Fernandez MM, Taranto NJ, Cajal SP, Margni RA, Castro E, Thomaz-Soccol V, Malchiodi EL, 2003. Characterization of human infection by Leishmania spp. in the northwest of Argentina: immune response, double infection with Trypanosoma cruzi and species of Leishmania involved. Parasitology 126 : 31–39.
  7. Marco JD, Barroso PA, Calvopina M, Kumazawa H, Furuya M, Korenaga M, Cajal SP, Mora MC, Rea MM, Borda CE, Basombrio MA, Taranto NJ, Hashiguchi Y, 2005. Species assignation of Leishmania from human and canine American tegumentary leishmaniasis cases by multilocus enzyme electrophoresis in north Argentina. Am J Trop Med Hyg 72 : 606–611.
  8. Salomon OD, Sosa Estani S, Canini L, Cordoba Lanus E, 2001. Tegumentary leishmaniasis in area with epidemic levels of transmission, Salta, Argentina, 1998. Medicina (B Aires) 61 : 284–290.
  9. Sosa-Estani S, Segura EL, Salomon OD, Gomez A, Peralta M, Coutada V, Ruiz LM, 2000. Tegumentary leishmaniasis in Northern Argentina: distribution of infection and disease, in three municipalities of Salta, 1990–1992. Rev Soc Bras Med Trop 33 : 573–582.
  10. Llanos Cuentas EA, Cuba CC, Barreto AC, Marsden PD, 1984. Clinical characteristics of human Leishmania braziliensis braziliensis infections. Trans R Soc Trop Med Hyg 78 : 845–846.
  11. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J, 2002. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 347 : 1739–1746.
  12. Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Diaz A, Luz M, Gutierrez P, Arboleda M, Berman JD, Junge K, Engel J, Sindermann H, 2004. Miltefosine for New World cutaneous leishmaniasis. Clin Infect Dis 38 : 1266–1272.
  13. Soto J, Soto P, 2006. Miltefosine: oral treatment of leishmaniasis. Expert Rev Anti Infect Ther 4 : 177–185.
  14. Soto J, Toledo J, Valda L, Balderrama M, Rea I, Parra R, Ardiles J, Soto P, Gomez A, Molleda F, Fuentelsaz C, Anders G, Sindermann H, Engel J, Berman J, 2007. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin Infect Dis 44 : 350–356.
  15. Yardley V, Croft SL, de Doncker S, Dujardin JC, Koirala S, Rijal S, Miranda C, Llanos-Cuentas A, Chappuis F, 2005. The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine. Am J Trop Med Hyg 73 : 272–275.
  16. Alrajhi AA, Ibrahim EA, de Vol EB, Khairat M, Faris RM, Maguire JH, 2002. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 346 : 891–895.
  17. Sivapalasingam S, Steigbigel N, 2005. Macrolides, clindamycin and ketolides. Mandell G, Bennett J, Dolin R, eds. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. Philadelphia, PA: Elsevier Churchill Livingstone, 396–417.
  18. Miller RS, Wongsrichanalai C, Buathong N, McDaniel P, Walsh DS, Knirsch C, Ohrt C, 2006. Effective treatment of uncomplicated Plasmodium falciparum malaria with azithromycin-quinine combinations: a randomized, dose-ranging study. Am J Trop Med Hyg 74 : 401–406.
  19. Bosch-Driessen LH, Verbraak FD, Suttorp-Schulten MS, van Ruyven RL, Klok AM, Hoyng CB, Rothova A, 2002. A prospective, randomized trial of pyrimethamine and azithromycin vs pyrimethamine and sulfadiazine for the treatment of ocular toxoplasmosis. Am J Ophthalmol 134 : 34–40.
  20. Boothby LA, Doering PL, 2001. FDA labeling system for drugs in pregnancy. Ann Pharmacother 35 : 1485–1489.
  21. Treadway G, Pontani D, 1996. Paediatric safety of azithromycin: worldwide experience. J Antimicrob Chemother 37 (Suppl C): 143–149.
  22. Ramsey PS, Vaules MB, Vasdev GM, Andrews WW, Ramin KD, 2003. Maternal and transplacental pharmacokinetics of azithromycin. Am J Obstet Gynecol 188 : 714–718.
  23. Dunne M, Fessel J, Kumar P, Dickenson G, Keiser P, Boulos M, Mogyros M, White AC Jr, Cahn P, O’Connor M, Lewi D, Green S, Tilles J, Hicks C, Bissett J, Schneider MM, Benner R, 2000. A randomized, double-blind trial comparing azithromycin and clarithromycin in the treatment of disseminated Mycobacterium avium infection in patients with human immunodeficiency virus. Clin Infect Dis 31 : 1245–1252.
  24. Gladue RP, Bright GM, Isaacson RE, Newborg MF, 1989. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother 33 : 277–282.
  25. Krolewiecki A, Leon S, Scott P, Abraham D, 2002. Activity of azithromycin against Leishmania major in vitro and in vivo. Am J Trop Med Hyg 67 : 273–277.
  26. Prata A, Silva-Vergara ML, Costa L, Rocha A, Krolewiecki A, Silva JC, de Paula EV, Pimenta Junior FG, Giraldo LE, 2003. Efficacy of azithromycin in the treatment of cutaneous leishmaniasis. Rev Soc Bras Med Trop 36 : 65–69.
  27. Silva-Vergara ML, Silva Lde A, Maneira FR, da Silva AG, Prata A, 2004. Azithromycin in the treatment of mucosal leishmaniasis. Rev Inst Med Trop Sao Paulo 46 : 175–177.
  28. Marco JD, Uezato H, Mimori T, Barroso PA, Korenaga M, Nonaka S, Basombrio MA, Taranto NJ, Hashiguchi Y, 2006. Are cytochrome B gene sequencing and polymorphism-specific polymerase chain reaction as reliable as multilocus enzyme electrophoresis for identifying Leishmania spp. from Argentina? Am J Trop Med Hyg 75 : 256–260.
  29. Daoud S, Boushi L, 2006. Azithromycin, ineffective in the treatment of old-world cutaneous leishmaniasis. Int J Dermatol 45 : 1126–1128.
  30. Soto J, Toledo JT, 2007. Oral miltefosine to treat new world cutaneous leishmaniasis. Lancet Infect Dis 7 : 7.
  31. Navin TR, Arana BA, Arana FE, Berman JD, Chajon JF, 1992. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis 165 : 528–534.
  32. Navin TR, Arana BA, Arana FE, de Merida AM, Castillo AL, Pozuelos JL, 1990. Placebo-controlled clinical trial of meglumine antimonate (glucantime) vs. localized controlled heat in the treatment of cutaneous leishmaniasis in Guatemala. Am J Trop Med Hyg 42 : 43–50.
  33. Andersen EM, Cruz-Saldarriaga M, Llanos-Cuentas A, Luz-Cjuno M, Echevarria J, Miranda-Verastegui C, Colina O, Berman JD, 2005. Comparison of meglumine antimoniate and pentamidine for Peruvian cutaneous leishmaniasis. Am J Trop Med Hyg 72 : 133–137.
  34. Oliveira-Neto MP, Schubach A, Mattos M, Goncalves-Costa SC, Pirmez C, 1997. A low-dose antimony treatment in 159 patients with American cutaneous leishmaniasis: extensive follow-up studies (up to 10 years). Am J Trop Med Hyg 57 : 651–655.
  35. Herwaldt BL, Berman JD, 1992. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg 46 : 296–306.
  36. Gerhardt SG, McDyer JF, Girgis RE, Conte JV, Yang SC, Orens JB, 2003. Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. Am J Respir Crit Care Med 168 : 121–125.
  37. Xu G, Fujita J, Negayama K, Yuube K, Hojo S, Yamaji Y, Kawanishi K, Takahara J, 1996. Effect of macrolide antibiotics on macrophage functions. Microbiol Immunol 40 : 473–479.
  38. Ouellette M, Drummelsmith J, Papadopoulou B, 2004. Leishmaniasis: drugs in the clinic, resistance and new developments. Drug Resist Updat 7 : 257–266.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2007.77.640
Loading
/content/journals/10.4269/ajtmh.2007.77.640
Loading

Data & Media loading...

  • Received : 04 Dec 2006
  • Accepted : 02 Jul 2007

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error